{
    "clinical_study": {
        "@rank": "66965", 
        "arm_group": {
            "arm_group_label": "Treatment", 
            "arm_group_type": "Experimental", 
            "description": "Eligible patients receive one cycle of Endostar monotherapy, two cycles of Endostar combined with chemotherapy (vinorelbine plus cisplatin) treatment, followed by Endostar plus radiotherapy treatment."
        }, 
        "brief_summary": {
            "textblock": "Primary objective: functional imaging and quantitative imaging detection of the effects of\n      Endostar combined with chemotherapy and radiotherapy on Non-small Cell Lung Cancer (NSCLC).\n\n      Secondary objective: To evaluate 1) the role of Endostar in regulating tumor vessels and\n      normalizing of microenvironment; 2) Toxicity of Endostar combined with chemotherapy."
        }, 
        "brief_title": "Effect of Endostar Combined With Chemotherapy and Radiotherapy on Blood Vessels and Microenvironment of Tumor for Non-small Cell Lung Cancer (NSCLC)", 
        "completion_date": {
            "#text": "October 2009", 
            "@type": "Actual"
        }, 
        "condition": "Non-small Cell Lung Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically or cytologically proven inoperable stage IIIb-IV NSCLC\n\n          -  ECOG PS 0-1\n\n          -  Life expectancy > 3 months\n\n          -  Adequate blood functions: Absolute neutrophil count (ANC) \u2265 1.5 x 109/L, platelet\n             count \u2265 100 x 109/L, and hemoglobin \u2265 9 g / dL\n\n          -  Adequate liver function: total bilirubin <1.5 times the upper limit of normal (ULN);\n             AST and ALT <2.5 times ULN in patients without liver metastases, <5 times ULN in\n             patients with liver metastases\n\n          -  Adequate renal function: serum creatinine \u2264 1.25 times ULN or calculated creatinine\n             clearance \u2265 50 mL / min and urinary protein <2+. In patients with baseline urinary\n             protein \u2265 2+, 24 hours urine should be collected and 24 hours urine protein \u2264 1g\n\n          -  International normalized ratio (INR) \u2264 1.5 and prothrombin time(PT) \u2264 1.5 times ULN\n             within 7 days before enrollment\n\n          -  Written informed consent\n\n        Exclusion Criteria:\n\n          -  Evidence of bleeding diathesis or coagulopathy\n\n          -  History of hemoptysis, defined as bright red blood more than half a teaspoon 3 months\n             before enrollment\n\n          -  Previously received chemotherapy and radiotherapy and biological targeted therapy\n\n          -  Uncontrolled hypertension (systolic blood pressure> 150 mmHg and/or diastolic blood\n             pressure> 100 mm Hg)\n\n          -  Clinically significant (ie, active) cardiovascular diseases, such as cerebrovascular\n             accident (within 6 months before initiating treatment), myocardial infarction (within\n             6 months before initiating treatment), unstable angina, congestive heart failure (New\n             York Heart Association class \u2265Grade II) , serious arrhythmia which needs medication\n             during the study and may affect the study or can not be controlled by drugs\n\n          -  Unhealed wounds, active peptic ulcer or fracture\n\n          -  Gastrointestinal fistula, gastrointestinal perforation or intra-abdominal abscess\n             within 6 months before enrollment\n\n          -  Women with intact uterus (menopause more than two years excluded) who are unwilling\n             to take effective non-hormonal contraception (IUD, spermicide barrier birth control\n             device or sterilization) during the study. Male who are unwilling to take effective\n             contraceptive measures during the study\n\n          -  Participated in other clinical trials within 28 days before the initiation of\n             treatment.\n\n          -  Allergic to any of the study drugs"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "15", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 16, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01687439", 
            "org_study_id": "NSCLC0901"
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment", 
                "description": "7.5mg/m2, D1-14", 
                "intervention_name": "Endostar", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Treatment", 
                "description": "25-30mg/m2, D1,8", 
                "intervention_name": "Vinorelbine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Treatment", 
                "description": "25 mg/m2, D1-3", 
                "intervention_name": "Cisplatin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Treatment", 
                "intervention_name": "Radiotherapy", 
                "intervention_type": "Radiation"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Vinorelbine", 
                "Cisplatin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "September 18, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Shanghai", 
                    "country": "China"
                }, 
                "name": "Fudan University Shanghai Cancer Center"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "Effect of Endostar Combined With Chemotherapy and Radiotherapy on Blood Vessels and Microenvironment of Tumor for Non-small Cell Lung Cancer", 
        "overall_official": [
            {
                "affiliation": "Fudan University", 
                "last_name": "Guoliang Jiang, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Fudan University", 
                "last_name": "Ming Fan, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2009", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Tumor blood volume", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "measure": "Tumor blood flow", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "measure": "Permeability-surface area product", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "measure": "18-FDG PET SUV values", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01687439"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Fudan University", 
            "investigator_full_name": "Fan Ming", 
            "investigator_title": "Associate Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "The incidence of adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "3 months"
        }, 
        "source": "Fudan University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Fudan University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2008", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2012"
    }
}